Anti-VEGF Market Size, Trends & Growth Analysis

Download Free Sample

Market Segmentation

Anti-VEGF Market, By Product (2022-2030)

Eylea
Lucentis
Beovu

Anti-VEGF Market, By Disease (2022-2030)

Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-Related Macular Degeneration

Anti-VEGF Market, By Drug (2022-2030)

Small Molecules
1. Pazopanib
2. Sunitinib
3. Sorafenib
4. Regorafenib
5. Cabozantinib
6. Lenvatinib
7. Ponatinib
8. Axitinib
9. Tivozanib
10. Vandetanib
11. Anlotinib
12. Apatinib
13. Fruquintinib
14. Surufatinib
Biologics
1. Bevacizumab
2. Aflibercept
3. Ramucirumab

Anti-VEGF Market, By Type (2022-2030)

VEGF-A Inhibitors
VEGF-B Inhibitors
VEGF-C Inhibitors
Placenta Growth Factor Inhibitors

Anti-VEGF Market, By Distribution Channel (2022-2030)

Hospitals
Specialty Clinics
Mail Order Pharmacies

Regional Anti-VEGF Market

North America
1. North America Anti-VEGF Market, By Product
  1. Eylea
  2. Lucentis
  3. Beovu
2. North America Anti-VEGF Market, By Disease
  1. Macular Edema
  2. Diabetic Retinopathy
  3. Retinal Vein Occlusion
  4. Age-Related Macular Degeneration
3. North America Anti-VEGF Market, By Drug
  1. Small Molecules
  2. Biologics
4. North America Anti-VEGF Market, By Type
  1. VEGF-A Inhibitors
  2. VEGF-B Inhibitors
  3. VEGF-C Inhibitors
  4. Placenta Growth Factor Inhibitors
5. North America Anti-VEGF Market, By Distribution Channel
  1. Hospitals
  2. Specialty Clinics
  3. Mail Order Pharmacies
6. U.S.
  1. U.S. Anti-VEGF Market, By Product
    1. Eylea
    2. Lucentis
    3. Beovu
  2. U.S. Anti-VEGF Market, By Disease
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-Related Macular Degeneration
  3. U.S. Anti-VEGF Market, By Drug
    1. Small Molecules
    2. Biologics
  4. U.S. Anti-VEGF Market, By Type
    1. VEGF-A Inhibitors
    2. VEGF-B Inhibitors
    3. VEGF-C Inhibitors
    4. Placenta Growth Factor Inhibitors
  5. U.S. Anti-VEGF Market, By Distribution Channel
    1. Hospitals
    2. Specialty Clinics
    3. Mail Order Pharmacies
7. Canada
Europe
1. Europe Anti-VEGF Market, By Product
  1. Eylea
  2. Lucentis
  3. Beovu
2. Europe Anti-VEGF Market, By Disease
  1. Macular Edema
  2. Diabetic Retinopathy
  3. Retinal Vein Occlusion
  4. Age-Related Macular Degeneration
3. Europe Anti-VEGF Market, By Drug
  1. Small Molecules
  2. Biologics
4. Europe Anti-VEGF Market, By Type
  1. VEGF-A Inhibitors
  2. VEGF-B Inhibitors
  3. VEGF-C Inhibitors
  4. Placenta Growth Factor Inhibitors
5. Europe Anti-VEGF Market, By Distribution Channel
  1. Hospitals
  2. Specialty Clinics
  3. Mail Order Pharmacies
6. U.K.
  1. U.K. Anti-VEGF Market, By Product
    1. Eylea
    2. Lucentis
    3. Beovu
  2. U.K. Anti-VEGF Market, By Disease
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-Related Macular Degeneration
  3. U.K. Anti-VEGF Market, By Drug
    1. Small Molecules
    2. Biologics
  4. U.K. Anti-VEGF Market, By Type
    1. VEGF-A Inhibitors
    2. VEGF-B Inhibitors
    3. VEGF-C Inhibitors
    4. Placenta Growth Factor Inhibitors
  5. U.K. Anti-VEGF Market, By Distribution Channel
    1. Hospitals
    2. Specialty Clinics
    3. Mail Order Pharmacies
7. Germany
8. France
9. Spain
10. Italy
11. Russia
12. Nordic
13. Benelux
14. Rest of Europe
APAC
1. APAC Anti-VEGF Market, By Product
  1. Eylea
  2. Lucentis
  3. Beovu
2. APAC Anti-VEGF Market, By Disease
  1. Macular Edema
  2. Diabetic Retinopathy
  3. Retinal Vein Occlusion
  4. Age-Related Macular Degeneration
3. APAC Anti-VEGF Market, By Drug
  1. Small Molecules
  2. Biologics
4. APAC Anti-VEGF Market, By Type
  1. VEGF-A Inhibitors
  2. VEGF-B Inhibitors
  3. VEGF-C Inhibitors
  4. Placenta Growth Factor Inhibitors
5. APAC Anti-VEGF Market, By Distribution Channel
  1. Hospitals
  2. Specialty Clinics
  3. Mail Order Pharmacies
6. China
  1. China Anti-VEGF Market, By Product
    1. Eylea
    2. Lucentis
    3. Beovu
  2. China Anti-VEGF Market, By Disease
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-Related Macular Degeneration
  3. China Anti-VEGF Market, By Drug
    1. Small Molecules
    2. Biologics
  4. China Anti-VEGF Market, By Type
    1. VEGF-A Inhibitors
    2. VEGF-B Inhibitors
    3. VEGF-C Inhibitors
    4. Placenta Growth Factor Inhibitors
  5. China Anti-VEGF Market, By Distribution Channel
    1. Hospitals
    2. Specialty Clinics
    3. Mail Order Pharmacies
7. Korea
8. Japan
9. India
10. Australia
11. Taiwan
12. South East Asia
13. Rest of Asia-Pacific
Middle East and Africa
1. Middle East and Africa Anti-VEGF Market, By Product
  1. Eylea
  2. Lucentis
  3. Beovu
2. Middle East and Africa Anti-VEGF Market, By Disease
  1. Macular Edema
  2. Diabetic Retinopathy
  3. Retinal Vein Occlusion
  4. Age-Related Macular Degeneration
3. Middle East and Africa Anti-VEGF Market, By Drug
  1. Small Molecules
  2. Biologics
4. Middle East and Africa Anti-VEGF Market, By Type
  1. VEGF-A Inhibitors
  2. VEGF-B Inhibitors
  3. VEGF-C Inhibitors
  4. Placenta Growth Factor Inhibitors
5. Middle East and Africa Anti-VEGF Market, By Distribution Channel
  1. Hospitals
  2. Specialty Clinics
  3. Mail Order Pharmacies
6. UAE
  1. UAE Anti-VEGF Market, By Product
    1. Eylea
    2. Lucentis
    3. Beovu
  2. UAE Anti-VEGF Market, By Disease
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-Related Macular Degeneration
  3. UAE Anti-VEGF Market, By Drug
    1. Small Molecules
    2. Biologics
  4. UAE Anti-VEGF Market, By Type
    1. VEGF-A Inhibitors
    2. VEGF-B Inhibitors
    3. VEGF-C Inhibitors
    4. Placenta Growth Factor Inhibitors
  5. UAE Anti-VEGF Market, By Distribution Channel
    1. Hospitals
    2. Specialty Clinics
    3. Mail Order Pharmacies
7. Turkey
8. Saudi Arabia
9. South Africa
10. Egypt
11. Nigeria
12. Rest of MEA
LATAM
1. LATAM Anti-VEGF Market, By Product
  1. Eylea
  2. Lucentis
  3. Beovu
2. LATAM Anti-VEGF Market, By Disease
  1. Macular Edema
  2. Diabetic Retinopathy
  3. Retinal Vein Occlusion
  4. Age-Related Macular Degeneration
3. LATAM Anti-VEGF Market, By Drug
  1. Small Molecules
  2. Biologics
4. LATAM Anti-VEGF Market, By Type
  1. VEGF-A Inhibitors
  2. VEGF-B Inhibitors
  3. VEGF-C Inhibitors
  4. Placenta Growth Factor Inhibitors
5. LATAM Anti-VEGF Market, By Distribution Channel
  1. Hospitals
  2. Specialty Clinics
  3. Mail Order Pharmacies
6. Brazil
  1. Brazil Anti-VEGF Market, By Product
    1. Eylea
    2. Lucentis
    3. Beovu
  2. Brazil Anti-VEGF Market, By Disease
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-Related Macular Degeneration
  3. Brazil Anti-VEGF Market, By Drug
    1. Small Molecules
    2. Biologics
  4. Brazil Anti-VEGF Market, By Type
    1. VEGF-A Inhibitors
    2. VEGF-B Inhibitors
    3. VEGF-C Inhibitors
    4. Placenta Growth Factor Inhibitors
  5. Brazil Anti-VEGF Market, By Distribution Channel
    1. Hospitals
    2. Specialty Clinics
    3. Mail Order Pharmacies
7. Mexico
8. Argentina
9. Chile
10. Colombia
11. Rest of LATAM

Related Reports

Anti-Venom Market

Global Report

Anti-venoms consist of anti-bodies that are used to treat venomous stings or bites. The growing prevalence of snake bites and other animals bite such as fish stings are the drivers of the anti-venom market. According to WHO, 4.5 to 5.4 million people

Buy Now

Purchase Benefits

Eligible for a free updated report next year
Completely customizable scope
30% discount on your next purchase
Dedicated account manager
Query resolution within 24 hours
Permission to print the report

Market Segmentation

Related Reports

Purchase Benefits

We are featured on :

Sample Details